Compare Abeona Therapeutics Inc (ABEO) vs Enovix Corporation (ENVX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Enovix Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Enovix Corporation trades at $4.98 (market cap $1.09B). The key difference: Enovix Corporation is far larger — about 2.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ABEO | ENVX | |
|---|---|---|
Market Cap | $373.32M | $1.09B |
Sector | Health | Technology |
52-Week High | $7.23 | $15.93 |
52-Week Low | $4.17 | $4.84 |
Enterprise Value | $228.22M | $1.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ENVX trades at $5.62, up 4.85% today, but technical indicators signal a bearish trend with support at $5 and resistance at $6. The company reported Q1 2026 revenue above guidance and an EPS beat, yet remains unprofitable with a net margin of -499.64%. Analyst consensus is bullish with a $12.75 price target, driven by growth in silicon-anode batteries for AI devices, smart eyewear, and defense markets.
The stock offers high-risk, high-reward potential given its speculative growth story versus persistent losses. Key catalysts include scaling commercial production and smartphone qualification, but execution risks and cash burn require careful monitoring. Investors should weigh analyst optimism against fundamental challenges in the competitive battery sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
